This statistic displays a projection of the top orphan molecular entities (approved in 2014) based on projected U.S. consensus sales in 2019. Biogen's Eloctate was approved in June 2014 and generated 58 million U.S. dollars in revenue during the same year in the United States. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Leading new orphan molecular entities by U.S. sales in 2014 and 2019 (in million U.S. dollars)*
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate. (October 30, 2015). Leading new orphan molecular entities by U.S. sales in 2014 and 2019 (in million U.S. dollars)* [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/373435/top-oprhan-drugs-molecular-entities-approved-by-us-sales/
Evaluate. "Leading new orphan molecular entities by U.S. sales in 2014 and 2019 (in million U.S. dollars)*." Chart. October 30, 2015. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/373435/top-oprhan-drugs-molecular-entities-approved-by-us-sales/
Evaluate. (2015). Leading new orphan molecular entities by U.S. sales in 2014 and 2019 (in million U.S. dollars)*. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/373435/top-oprhan-drugs-molecular-entities-approved-by-us-sales/
Evaluate. "Leading New Orphan Molecular Entities by U.S. Sales in 2014 and 2019 (in Million U.S. Dollars)*." Statista, Statista Inc., 30 Oct 2015, https://www-statista-com.ezproxy.canberra.edu.au/statistics/373435/top-oprhan-drugs-molecular-entities-approved-by-us-sales/
Evaluate, Leading new orphan molecular entities by U.S. sales in 2014 and 2019 (in million U.S. dollars)* Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/373435/top-oprhan-drugs-molecular-entities-approved-by-us-sales/ (last visited November 10, 2024)
Leading new orphan molecular entities by U.S. sales in 2014 and 2019 (in million U.S. dollars)* [Graph], Evaluate, October 30, 2015. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/373435/top-oprhan-drugs-molecular-entities-approved-by-us-sales/
